Hiroshi Sugimoto | Director
Takeda Pharmaceuticals

Dr. Sugimoto is the Director at Takeda Development Center Americas Inc., leading Nonclinical genomic/proteomic biomarker research to support oncology, cell therapy and gastroenterology disease programs. He also serves as the nonclinical pharmacokinetics project representative to support the cell therapy program IND submission. Dr. Sugimoto received a Ph.D. in Pharmaceutical Science from the University of Shizuoka, Japan, and an MBA in Health Sector Management from Boston University. He has been a chair of the Applied Pharmaceutical Analysis (APA) 2024 in Boston, co-chair of the AAPS Gene and Cell Therapy Products biomarker/bioanalytical subteam, and reviewer for the MassNextGen initiative. He has contributed to multiple scientific journals, including AAPS Journal, Analytical Chemistry, Bioanalysis, Drug Metabolism and Disposition, and Patent submission.